Cargando…
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particula...
Autores principales: | Johnson, J I, Decker, S, Zaharevitz, D, Rubinstein, L V, Venditti, J M, Schepartz, S, Kalyandrug, S, Christian, M, Arbuck, S, Hollingshead, M, Sausville, E A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363645/ https://www.ncbi.nlm.nih.gov/pubmed/11355958 http://dx.doi.org/10.1054/bjoc.2001.1796 |
Ejemplares similares
-
Azure B as a novel cyanide antidote: Preclinical in-vivo studies
por: Haouzi, Philippe, et al.
Publicado: (2020) -
ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies
por: Hollingshead, Melinda G., et al.
Publicado: (2022) -
P21-dependent G (1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
por: Sandor, V, et al.
Publicado: (2000) -
From clinical specimens to human cancer preclinical models—a journey the NCI‐cell line database—25 years later
por: Mulshine, James L., et al.
Publicado: (2019) -
Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo
por: Conradie, M M, et al.
Publicado: (2007)